Named to the 2024 CB Insights AI 100 List recognized for achievements in bringing healthcare AI from the lab to the clinic at scale and at speed

NEW YORK, April 2, 2024 /PRNewswire/ — CB Insights today named to its eighth-annual AI 100, showcasing the 100 most promising private AI companies of 2024.

“AI is taking off at lightning speed, and it’s not just big tech companies at the forefront of it,” said Deepashri Varadharajan, director of AI research at CB Insights. “Our AI 100 winners – many of them early stage startups, some with very small teams – are pushing the boundaries of AI in everything from game development and battery design to agentic AI systems.”

“Regulatory tailwinds coming from many directions are putting AI validation under an international spotlight, signaling an end to the ‘Wild West’ era of AI in healthcare. We are thrilled to have received this level of recognition as a young organization developing the mission-critical infrastructure, equipped with the necessary tools and guardrails to protect and serve all AI stakeholders in the ecosystem, from patients and health systems to government agencies and technology developers,” asserted Dr. Enes Hosgor, CEO and founder of

The 100 winners were chosen based on several factors, including CB Insights’ data on deal activity, industry partnerships, team strength, investor strength, patent activity, and proprietary Mosaic Scores. We also analyzed CB Insights’ exclusive interviews with software buyers and dug into Analyst Briefings submitted directly to us by startups. is spearheading a groundbreaking era in medical AI, akin to the transformative impact of electricity. Our core objective is to establish a robust infrastructure that ensures the safety, effectiveness, and accessibility of AI in healthcare.

Central to our approach is a rigorous AI validation process, facilitating reliability and regulatory compliance. With our healthcare-tailored and AI-native platform and strategic partnerships, including data custodians and expert physician annotators, we ensure precision and adherence to industry and regulatory standards.

This year, has achieved remarkable milestones, including selection for the CancerX Accelerator, a part of the White House moonshot initiative; and joining prestigious organizations like the U.S. AI Safety Institute Consortium under NIST and the U.S. Department of Commerce; and VALID AI, a collaborative comprising prominent health systems driving the adoption of responsible AI in healthcare. Our international expansion, crucial to our AI assurance network, is exemplified by our partnership with Trillium Health Partners based in Canada, further cementing our commitment to global impact.

As leaders in responsible AI, remains steadfast in our mission to revolutionize healthcare through cutting-edge technology and unwavering excellence.

Quick facts on the 2024 AI 100:

  • 16 countries represented, from the US to France to South Africa
  • 30+ categories of solutions, from foundation models to humanoids
  • 68% early-stage startups building virtual worlds, autonomous factories, language models for under-represented languages, and more
  • 600+ business relationships since 2016 with industry leaders like Toyota, Netflix, and the World Bank

About CB Insights
CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit

Gesund is the world’s premier AI assurance platform in healthcare, dedicated to advancing clinical-grade AI solutions to market. Backed by leading investors like Merck GHI, McKesson, Northpond, and 500, Gesund orchestrates the entire AI lifecycle for all AI developers such as pharmaceutical and medical device companies. Our pioneering AI-native platform offers versatile deployment options (airgapped vs. private cloud), ensuring rapid engagement with healthcare providers and board-certified physician experts annotators.
To learn more visit

James Christopherson
PR Manager

This release was issued through WebWire®. For more information, visit

Cision View original content:


error: Content is protected !!